
Abbott India Ltd. share price
NSE: ABBOTINDIA · Healthcare
₹25,980.00 -1.74%
Closing price data, updated 17 Nov 2026. 52-week range: -15.2% from high, +5.4% above low.
Price₹25,980.00
Market cap₹55,206 Cr
P/E33.4
P/B12.93
ROE34.5%
ROCE41.9%
Debt / equity0.04
Dividend yield2.53%
EPS₹777.84
Book value₹2,009.57
Operating margin26.3%
Dipscan score69 / 100
Share: WhatsAppX / TwitterTelegram
Abbott India Ltd. shareholding pattern
As of Sep 2026: Promoters 74.99%, FIIs 0.40%, DIIs 8.99%, Government 0.00%, Public 13.19%, Others 2.44%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% |
| FIIs | 0.40% | 0.38% | 0.26% | 0.18% | 0.16% | 0.16% |
| DIIs | 8.99% | 8.78% | 8.93% | 9.00% | 9.11% | 9.19% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 13.19% | 13.41% | 13.38% | 13.42% | 13.43% | 13.35% |
| Others | 2.44% | 2.44% | 2.43% | 2.42% | 2.31% | 2.31% |
| No. of Shareholders | 75,769 | 78,320 | 75,866 | 75,801 | 71,199 | 67,584 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -1.74% | -1.39% | -1.20% | -5.94% | -5.60% | -12.08% |
Growth
| Sales growth, 3 years | +9.0% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +17.8% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | +11.0% |
| Latest quarter profit vs last year | +9.2% |
Strengths and weaknesses
Strengths
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
- Company has been maintaining a healthy dividend payout of 77.9%
Weaknesses
- Stock is trading at 12.9 times its book value
- The company has delivered a poor sales growth of 9.96% over past five years.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Abbott India Ltd.?
Abbott India Ltd. (ABBOTINDIA) last closed at ₹25,980.00 (-1.74% on the day).
What is the market cap of Abbott India Ltd.?
About ₹55,206 Cr.
What is the P/E ratio of Abbott India Ltd.?
The price-to-earnings ratio is 33.4, and return on equity is 34.5%.
Figures are calculated from company results and exchange prices and are for information only.